• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Characteristics and management of patients with stroke and major hemorrhagic episodes with atrial fibrillation under vitamin K antagonist therapy. EVENTHO study
CONCLUSIONS: In the sample studied, half of the AF patients who suffered stroke/SE or major hemorrhagic episode had inadequate TTR and, despite this, after hospital discharge, they restarted treatment with VKA. These results highlight the need to evaluate safer and effective therapeutic alternatives in AF patients with poor TTR control after suffering a stroke/SE or major hemorrhagic episode.PMID:35120766 | DOI:10.1016/j.medcli.2021.12.004
Source: Medicina Clinica - February 5, 2022 Category: General Medicine Authors: Olga Gav ín Vanessa Rold án Pilar Llamas-Sillero Amparo Santamar ía Daniel Arum í Susana Fern ández de Cabo Source Type: research

Gender differences in antithrombotic treatment in patients with atrial fibrillation from Spain versus the rest of Western Europe. GLORIA-AF Program
CONCLUSIONS: OAC rates were higher in Spain as compared to rWE. More women received OACs in Spain, while in rWE no difference by gender was observed. DOACs in rWE are the most prescribed OAC while in Spain, due to prescription barriers, its use remains low for both genders and VKAs are preferred. Spanish women received more DOACs compared to men. (NCT01468701).PMID:34895750 | DOI:10.1016/j.medcli.2021.09.016
Source: Medicina Clinica - December 13, 2021 Category: General Medicine Authors: Jos é L López-Sendón David Alonso-Rodr íguez Gonzalo Bar ón-Esquivias Juan Cosin-Sales Francisco Mar ín Jordi Galera-Llorca Natalia Jim énez Sabrina Marler Menno V Huisman Gregory Y H Lip Spanish GLORIA-AF investigators Source Type: research

Patient characteristics and stroke and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban and vitamin K antagonists: a Spanish real-world study.
Conclusion: Patients prescribed apixaban for the treatment of nonvalvular atrial fibrillation had lower rates of thromboembolic events and minor/major bleeding than patients on acenocoumarol. PMID: 31333045 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - July 25, 2019 Category: General Medicine Tags: J Comp Eff Res Source Type: research